TY - JOUR
T1 - Outcomes of adjunctive therapy with intravenous cefoperazone-sulbactam for ventilator-associated pneumonia due to carbapenem-resistant Acinetobacter baumannii
AU - Kanchanasuwan, Siripen
AU - Kositpantawong, Narongdet
AU - Singkhamanan, Kamonnut
AU - Hortiwakul, Thanaporn
AU - Charoenmak, Boonsri
AU - Nwabor, Ozioma F.
AU - Doi, Yohei
AU - Chusri, Sarunyou
N1 - Publisher Copyright:
© 2021 Kanchanasuwan et al.
PY - 2021
Y1 - 2021
N2 - Introduction: The efficacy of adjunctive therapy with cefoperazone-sulbactam (CEP-SUL) for ventilator-associated pneumonia (VAP) due to carbapenem-resistant A. baumannii (CRAB) is unclear. Methods: We retrospectively analyzed the therapeutic effect of adding CEP-SUL to standard regimens for VAP due to CRAB. Patients with VAP due to CRAB strains that were susceptible to CEP-SUL were enrolled into the study. The patients were divided into two groups: Those who receive cefoperazone-sulbactam (CEP-SUL+), and those who did not receive cefoperazone-sulbactam (CEP-SUL). Mortality rates and resource utilization of these two groups were compared. Factors associated with mortality were explored. Results: Eighty patients were enrolled into the study, 52 CEP-SUL+ and 28 CEP-SUL–. The baseline characteristics of the two groups were comparable, except for median Acute Physiology and Chronic Health Evaluation (APACHE) II score which was significantly higher for CEP-SUL+. Thirty-day, and in-hospital mortality rates for CEP-SUL+ were significantly lower than CEP-SUL– with values of 35%, 39% and 61%, 68%, for CEPSUL+ and CEP-SUL–, respectively. The survival rate for CEP-SUL+ was significantly higher compared with CEP-SUL– (P < 0.001). The number of hospital days, ventilator days since diagnosis of VAP and hospital costs were lower for CEP-SUL+. Conclusion: Overall results suggested that patients with VAP due to CRAB strains who received adjunctive therapy with CEP-SUL had lower mortality rates and resource utilization compared with CEP-SUL–.
AB - Introduction: The efficacy of adjunctive therapy with cefoperazone-sulbactam (CEP-SUL) for ventilator-associated pneumonia (VAP) due to carbapenem-resistant A. baumannii (CRAB) is unclear. Methods: We retrospectively analyzed the therapeutic effect of adding CEP-SUL to standard regimens for VAP due to CRAB. Patients with VAP due to CRAB strains that were susceptible to CEP-SUL were enrolled into the study. The patients were divided into two groups: Those who receive cefoperazone-sulbactam (CEP-SUL+), and those who did not receive cefoperazone-sulbactam (CEP-SUL). Mortality rates and resource utilization of these two groups were compared. Factors associated with mortality were explored. Results: Eighty patients were enrolled into the study, 52 CEP-SUL+ and 28 CEP-SUL–. The baseline characteristics of the two groups were comparable, except for median Acute Physiology and Chronic Health Evaluation (APACHE) II score which was significantly higher for CEP-SUL+. Thirty-day, and in-hospital mortality rates for CEP-SUL+ were significantly lower than CEP-SUL– with values of 35%, 39% and 61%, 68%, for CEPSUL+ and CEP-SUL–, respectively. The survival rate for CEP-SUL+ was significantly higher compared with CEP-SUL– (P < 0.001). The number of hospital days, ventilator days since diagnosis of VAP and hospital costs were lower for CEP-SUL+. Conclusion: Overall results suggested that patients with VAP due to CRAB strains who received adjunctive therapy with CEP-SUL had lower mortality rates and resource utilization compared with CEP-SUL–.
UR - http://www.scopus.com/inward/record.url?scp=85104280252&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85104280252&partnerID=8YFLogxK
U2 - 10.2147/IDR.S305819
DO - 10.2147/IDR.S305819
M3 - Article
AN - SCOPUS:85104280252
SN - 1178-6973
VL - 14
SP - 1255
EP - 1264
JO - Infection and Drug Resistance
JF - Infection and Drug Resistance
ER -